Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;50(2):110-31.
doi: 10.1016/j.jadohealth.2011.10.010.

Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review

Sarah M Tiggelaar  1 , Margaret J Lin, Raphael P Viscidi, Jia Ji, Jennifer S Smith
Affiliations
Review

Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review

Sarah M Tiggelaar et al. J Adolesc Health. 2012 Feb.

Abstract

Purpose: Global data on human papillomavirus (HPV) serological and deoxyribonucleic acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies.

Methods: We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV-16, -18, -6, and -11.

Results: One hundred seventeen studies were included; participants' ages ranged from several hours to >90 years. HPV-16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than among men, and peaked around ages 25-40 years. HPV-18 seroprevalence was generally lower than HPV-16 with a later age peak. Data were limited for HPV-6 and -11, both of which peaked at ages similar to HPV-18. Among 9-26-year-old females, HPV-16 seroprevalence ranged from 0%-31% in North America, 21%-30% in Africa, 0%-23% in Asia/Australia, 0%-33% in Europe, and 13%-43% in Central and South America. HPV-16/-18 DNA prevalence peaked 10-15 years before corresponding HPV-16/-18 antibody prevalence.

Conclusions: Females within the HPV vaccine-eligible age-group (9-26 years) had a range of dual HPV-16 DNA and serology negativity from 81%-87%, whereas 90%-98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age-specific prevalence of HPV 16 DNA and antibodies against HPV 16 for studies with age-trend data, stratified by study area (16,19,29,57,58,62,116). All studies with age-trend data had only female participants.
Figure 2
Figure 2
Prevalence of different combinations of HPV 16 DNA and antibodies against HPV 16, stratified by study area. All studies with DNA and antibody data had only female participants.
See this image and copyright information in PMC

References

    1. Human Papillomaviruses . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer (IARC); Lyon, France: 2007.
    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide cancer burden in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. DOI: 10.1002/ijc.25516. - PubMed
    1. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65. DOI: 10.1016/S0140-6736(04)17398-4. - PubMed
    1. Group TFIS Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. DOI:10.1056/NEJMoa061741. - PubMed
    1. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–66. DOI: 10.1038/sj.bjc.6603469. - PMC - PubMed

Publication types